Mariano A, Di Carlo A, Pastan I, Macchia V
Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita di Napoli, 80131 Napoli, Italy.
Int J Oncol. 2000 Mar;16(3):549-53. doi: 10.3892/ijo.16.3.549.
In this study we show by immunoblotting that B1 and B3, two newly isolated monoclonal antibodies, react with a variety of glycoproteins with different molecular weights expressed in stomach, pancreas, colorectal and breast cancers. The pattern of reactivity differed among cancers arising in different tissues, although no correlation has been observed with the histopathological characteristics of the lesion analysed. MAb B3 and MAb B1, have a limited reactivity with peritumoral tissues, whereas react very strongly with metastatic lesion. Because of the limited reactivity of these antibodies with normal tissue, MAbs B3 and B1, armed with toxin in the form of recombinant immunotoxins, can be useful in treating certain kinds of cancer such as metastatic lesions. However, until current clinical trials are completed, we will not know if they will be helpful in cancer treatment.
在本研究中,我们通过免疫印迹法表明,两种新分离的单克隆抗体B1和B3与胃癌、胰腺癌、结直肠癌和乳腺癌中表达的多种不同分子量的糖蛋白发生反应。不同组织来源的癌症之间反应模式不同,尽管未观察到与所分析病变的组织病理学特征存在相关性。单克隆抗体B3和单克隆抗体B1与肿瘤周围组织的反应有限,而与转移灶反应非常强烈。由于这些抗体与正常组织的反应有限,以重组免疫毒素形式携带毒素的单克隆抗体B3和B1可用于治疗某些类型的癌症,如转移灶。然而,在当前的临床试验完成之前,我们尚不清楚它们是否对癌症治疗有帮助。